Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Deletion 5q35 refers to the different congenital malformation syndromes resulting from deletions of variable extent of the terminal part of the long arm of chromosome 5 (5q), spanning the region from 5q35.1 to 5q35.3 . The most significant anomaly is a recurring deletion in 5q35.2 comprising the NSD1 gene that causes Sotos syndrome that is characterized by cardinal features including excessive growth during childhood, macrocephaly, distinctive facial gestalt and various degrees of learning difficulty. Subtelomeric deletions of the terminal 3.5 Mb region on 5q35.3 are very rare, characterized by prenatal lymphedema with increased nuchal translucency, pronounced muscular hypotonia in infancy, borderline intelligence, postnatal short stature due to growth hormone deficiency, and a variety of minor anomalies such as mildly bell-shaped chest, minor congenital heart defects and a distinct facial gestalt. Larger deletions including bands 5q35.1, 5q35.2 and 5q35.3 cause a more severe phenotype that associates severe developmental delay with microcephaly, and significant cardiac defects (e.g. atrial septal defect with/without atrioventricular conduction defects, Ebstein anomaly, tetralogy of Fallot) linked to haploinsufficiency of NKX2.5 (5q35.1). Various combinations of signs may result from deletions of variable extent depending on the genes comprised in the deleted segment.
Biomarker and diagnostic research for deletion 5q35 has been reported in the published literature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for deletion 5q35.
4 publications have been identified in PubMed for deletion 5q35. Research spans Case Report / Case Series (50%), Diagnostic / Biomarker (25%), and Basic Science / Preclinical (25%).
Su Y (2025). [PMID: 40819321](https://pubmed.ncbi.nlm.nih.gov/40819321/). *Hum Cell*. [Basic Science / Preclinical]
Mizuguchi T (2025). [PMID: 39966947](https://pubmed.ncbi.nlm.nih.gov/39966947/). *Clin Epigenetics*. [Diagnostic / Biomarker]
Bargenda-Lange A (2025). [PMID: 41303235](https://pubmed.ncbi.nlm.nih.gov/41303235/). *J Clin Med*. [Case Report / Case Series]
González-Rodríguez JD (2025). [PMID: 37559368](https://pubmed.ncbi.nlm.nih.gov/37559368/). *J Clin Res Pediatr Endocrinol*. [Case Report / Case Series]
Data assembled from 3 of 12 sources · Last updated Sep 18, 2026, 4:23 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center